董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stan K. Erickson | 男 | Independent Director and Vice Chair of the Board | 76 | 14.18万美元 | 4.03 | 2026-09-30 |
| Andrea M. Walsh | 女 | Independent Director | 63 | 13.30万美元 | 1.80 | 2026-09-30 |
| Joseph L. Galatowitsch | 男 | Independent Director | 68 | 12.80万美元 | 1.50 | 2026-09-30 |
| James L. Cunniff | 男 | Chief Executive Officer, Director and President | 61 | 181.29万美元 | 30.73 | 2026-09-30 |
| Gregory J. Fluet | 男 | Independent Director | 57 | 13.50万美元 | 2.10 | 2026-09-30 |
| Kathleen A. Tune | 女 | Independent Director | 62 | 16.05万美元 | 1.50 | 2026-09-30 |
| Kathleen S. Skarvan | 女 | Chair of the Board and Independent Director | 70 | 15.30万美元 | 21.59 | 2026-09-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James L. Cunniff | 男 | Chief Executive Officer, Director and President | 61 | 181.29万美元 | 30.73 | 2026-09-30 |
| Bradley M. Nagel | 男 | Chief Financial Officer | 44 | 83.62万美元 | 3.90 | 2026-09-30 |
董事简历
中英对照 | 中文 | 英文- Stan K. Erickson
-
Stan K. Erickson，2014年11月在股东2014财年年度会议上被第一个选到董事会。他目前是一家他于2013年9月联合创立的、提供资本和咨询服务的公司- Liberty Capital, Inc.的总裁和首席执行官。2012年11月，他从供职了32年的ZieglerCat, Inc.退休，该公司是美国最大的Caterpillar经销商之一，他最近担任该公司的总裁和首席运营官。他是United States Marine Corps的一位老将，持有Minnesota大学的商务学位、注册会计师协会证；是从担任审计员和税务专家开始他的商业职业生涯的。他曾积极参与数个私有企业的董事会、咨询委员会和协会。
Stan K. Erickson provides a strong perspective on financing, investment, acquisition and operating strategies, public company regulatory compliance issues, and investor relations. Mr. Erickson currently serves as President and Chief Executive Officer of Liberty Capital, Inc., which he co founded in 2013 to provide capital and advisory services to both pre and post commercialization organizations in various industries, including medical device and technology. Over his 32 year career at Ziegler, he was responsible for developing and executing strategies to achieve growth through market share gains and acquisitions. Stan K. Erickson has served as President and CEO of Liberty Capital, Inc., and as President and COO of Ziegler, Inc. He is a United States Marine Corps Veteran and has previously worked as an Auditor and Tax Professional at Baker Tilly US LLP. He holds a BS in Business Administration from the University of Minnesota and is a Certified Public Accountant (Inactive). - Stan K. Erickson，2014年11月在股东2014财年年度会议上被第一个选到董事会。他目前是一家他于2013年9月联合创立的、提供资本和咨询服务的公司- Liberty Capital, Inc.的总裁和首席执行官。2012年11月，他从供职了32年的ZieglerCat, Inc.退休，该公司是美国最大的Caterpillar经销商之一，他最近担任该公司的总裁和首席运营官。他是United States Marine Corps的一位老将，持有Minnesota大学的商务学位、注册会计师协会证；是从担任审计员和税务专家开始他的商业职业生涯的。他曾积极参与数个私有企业的董事会、咨询委员会和协会。
- Stan K. Erickson provides a strong perspective on financing, investment, acquisition and operating strategies, public company regulatory compliance issues, and investor relations. Mr. Erickson currently serves as President and Chief Executive Officer of Liberty Capital, Inc., which he co founded in 2013 to provide capital and advisory services to both pre and post commercialization organizations in various industries, including medical device and technology. Over his 32 year career at Ziegler, he was responsible for developing and executing strategies to achieve growth through market share gains and acquisitions. Stan K. Erickson has served as President and CEO of Liberty Capital, Inc., and as President and COO of Ziegler, Inc. He is a United States Marine Corps Veteran and has previously worked as an Auditor and Tax Professional at Baker Tilly US LLP. He holds a BS in Business Administration from the University of Minnesota and is a Certified Public Accountant (Inactive).
- Andrea M. Walsh
-
Andrea M. Walsh目前担任HealthPartners的总裁兼首席执行官，这是一家总部位于明尼苏达州、价值90亿美元的非营利性综合健康系统，提供护理、健康支持、保险、研究和教育项目。自2017年以来，她一直担任这一职务，在HealthPartners 30多年的职业生涯中，Walsh女士担任过几个责任越来越大的职位，包括2002年4月至2017年5月担任执行副总裁和首席营销官，以及1994年至1999年担任高级副总裁和公司法律顾问。作为总裁兼首席执行官，沃尔什女士领导着一个约2.8万人的团队，其中包括一个拥有1900多名医生和1200名高级实践临床医生的多专科集团诊所，他们共同为明尼苏达州和威斯康星州超过140万名患者提供服务，以及一个为全国160万名成员提供服务的健康计划以及一个研究和教育机构。Andrea M. Walsh在HealthPartners，Inc.拥有丰富的执行经验，曾担任总裁兼首席执行官、执行副总裁兼首席营销官、高级副总裁兼公司法律顾问。她拥有堪萨斯大学工商管理与英语学士学位和明尼苏达大学法学院京东学位。
Andrea M. Walsh currently serves as President and Chief Executive Officer of HealthPartners, a $9.0 billion Minnesota based non profit integrated health system that provides care, health support, insurance coverage, research and education programs. She has been in this role since 2017 and over her 30+ year career with HealthPartners, Ms. Walsh has held several positions of increasing responsibility, including as Executive Vice President and Chief Marketing Officer, from April 2002 to May 2017, and as Senior Vice President and Corporate Counsel from 1994 to 1999. In her role as President and Chief Executive Officer, Ms. Walsh leads a team of approximately 28,000 people, including a multi specialty group practice with over 1,900 physicians and 1,200 advanced practice clinicians, who collectively serve more than 1.4 million patients in Minnesota and Wisconsin, and a health plan serving 1.6 million members across the country as well as a research and education institute. Andrea M. Walsh has extensive executive experience at HealthPartners, Inc., having served as President & CEO, Executive VP & CMO, and SVP & Corporate Counsel. She holds a BA in Business Administration & English from the University of Kansas and a JD from the University of Minnesota Law School. - Andrea M. Walsh目前担任HealthPartners的总裁兼首席执行官，这是一家总部位于明尼苏达州、价值90亿美元的非营利性综合健康系统，提供护理、健康支持、保险、研究和教育项目。自2017年以来，她一直担任这一职务，在HealthPartners 30多年的职业生涯中，Walsh女士担任过几个责任越来越大的职位，包括2002年4月至2017年5月担任执行副总裁和首席营销官，以及1994年至1999年担任高级副总裁和公司法律顾问。作为总裁兼首席执行官，沃尔什女士领导着一个约2.8万人的团队，其中包括一个拥有1900多名医生和1200名高级实践临床医生的多专科集团诊所，他们共同为明尼苏达州和威斯康星州超过140万名患者提供服务，以及一个为全国160万名成员提供服务的健康计划以及一个研究和教育机构。Andrea M. Walsh在HealthPartners，Inc.拥有丰富的执行经验，曾担任总裁兼首席执行官、执行副总裁兼首席营销官、高级副总裁兼公司法律顾问。她拥有堪萨斯大学工商管理与英语学士学位和明尼苏达大学法学院京东学位。
- Andrea M. Walsh currently serves as President and Chief Executive Officer of HealthPartners, a $9.0 billion Minnesota based non profit integrated health system that provides care, health support, insurance coverage, research and education programs. She has been in this role since 2017 and over her 30+ year career with HealthPartners, Ms. Walsh has held several positions of increasing responsibility, including as Executive Vice President and Chief Marketing Officer, from April 2002 to May 2017, and as Senior Vice President and Corporate Counsel from 1994 to 1999. In her role as President and Chief Executive Officer, Ms. Walsh leads a team of approximately 28,000 people, including a multi specialty group practice with over 1,900 physicians and 1,200 advanced practice clinicians, who collectively serve more than 1.4 million patients in Minnesota and Wisconsin, and a health plan serving 1.6 million members across the country as well as a research and education institute. Andrea M. Walsh has extensive executive experience at HealthPartners, Inc., having served as President & CEO, Executive VP & CMO, and SVP & Corporate Counsel. She holds a BA in Business Administration & English from the University of Kansas and a JD from the University of Minnesota Law School.
- Joseph L. Galatowitsch
-
Joseph L. Galatowitsch最近担任Guidehouse Consulting的合伙人和医疗技术实践负责人，Guidehouse Consulting是一家为公共和商业市场提供咨询服务的全球领先供应商，在管理、技术和风险咨询方面拥有广泛的能力。他还在2008年1月至2016年8月期间共同创立并担任Dymedex Consulting，LLC总裁，该公司被Navigant收购，直至2020年9月退休。他开创并为世界提供了新的概念框架，用于评估机会和推动颠覆性新医疗技术的临床采用。在美敦力，他在美敦力的心律管理部门领导和协调全球市场开发工作。Joseph L. Galatowitsch在咨询和营销方面拥有丰富的经验，曾担任Guidehouse Consulting的合伙人以及Dymedex Consulting LLC的联合创始人和总裁。他还曾在美敦力、PLC担任战略营销高级总监，并在3M公司担任营销和业务管理部门的领导职务。他拥有马凯特大学生物医学工程学士学位和圣托马斯奥普斯商学院市场营销MBA学位。
Joseph L. Galatowitsch most recently served as a Partner and Medtech practice leader at Guidehouse Consulting, a leading global provider of consulting services to the public and commercial markets with broad capabilities in management, technology, and risk consulting. He also co founded and served as President of Dymedex Consulting, LLC from January 2008 through August 2016 when it was acquired by Navigant up until his retirement in September 2020. He pioneered and provided new to the world conceptual frameworks for assessing opportunities and driving clinical adoption of disruptive new medical technologies. At Medtronic, he led and coordinated global market development efforts in Medtronic's cardiac rhythm management division. Joseph L. Galatowitsch has extensive experience in consulting and marketing, having served as a Partner at Guidehouse Consulting and as Co Founder and President of Dymedex Consulting LLC. He also held leadership roles at Medtronic, PLC as Senior Director of Strategic Marketing, and at 3M Company in Marketing and Business Management. He holds a BS in Biomedical Engineering from Marquette University and an MBA in Marketing from St. Thomas Opus College of Business. - Joseph L. Galatowitsch最近担任Guidehouse Consulting的合伙人和医疗技术实践负责人，Guidehouse Consulting是一家为公共和商业市场提供咨询服务的全球领先供应商，在管理、技术和风险咨询方面拥有广泛的能力。他还在2008年1月至2016年8月期间共同创立并担任Dymedex Consulting，LLC总裁，该公司被Navigant收购，直至2020年9月退休。他开创并为世界提供了新的概念框架，用于评估机会和推动颠覆性新医疗技术的临床采用。在美敦力，他在美敦力的心律管理部门领导和协调全球市场开发工作。Joseph L. Galatowitsch在咨询和营销方面拥有丰富的经验，曾担任Guidehouse Consulting的合伙人以及Dymedex Consulting LLC的联合创始人和总裁。他还曾在美敦力、PLC担任战略营销高级总监，并在3M公司担任营销和业务管理部门的领导职务。他拥有马凯特大学生物医学工程学士学位和圣托马斯奥普斯商学院市场营销MBA学位。
- Joseph L. Galatowitsch most recently served as a Partner and Medtech practice leader at Guidehouse Consulting, a leading global provider of consulting services to the public and commercial markets with broad capabilities in management, technology, and risk consulting. He also co founded and served as President of Dymedex Consulting, LLC from January 2008 through August 2016 when it was acquired by Navigant up until his retirement in September 2020. He pioneered and provided new to the world conceptual frameworks for assessing opportunities and driving clinical adoption of disruptive new medical technologies. At Medtronic, he led and coordinated global market development efforts in Medtronic's cardiac rhythm management division. Joseph L. Galatowitsch has extensive experience in consulting and marketing, having served as a Partner at Guidehouse Consulting and as Co Founder and President of Dymedex Consulting LLC. He also held leadership roles at Medtronic, PLC as Senior Director of Strategic Marketing, and at 3M Company in Marketing and Business Management. He holds a BS in Biomedical Engineering from Marquette University and an MBA in Marketing from St. Thomas Opus College of Business.
- James L. Cunniff
-
James L. Cunniff是医疗保健领域一位经验丰富的高管，直接了解Electromed的业务和运营，因为他目前担任Electromed, Inc.的总裁兼首席执行官。在2023年7月加入Electromed之前，他曾担任Provista，Inc.（20172022）和Denver Solutions，LLC（20152017）的总裁兼首席执行官。James L. Cunniff拥有丰富的行政领导经验，曾在Electromed, Inc.担任总裁兼首席执行官、董事会成员，并在Provista，Inc.担任总裁兼首席执行官。他还曾在Denver Solutions LLC（d/b/a Leiters Health）担任总裁、首席执行官和董事会成员等职务。在担任这些职务之前，他曾担任Acelity L.P. Inc.美洲区高级副总裁，以及史赛克公司多个部门总裁。他拥有伊利诺伊大学厄巴纳香槟分校的广告和商业学士学位，并在哈佛商学院完成了高级管理课程。
James L. Cunniff is a seasoned executive in the healthcare space with a direct knowledge of Electromed's business and operations as he currently serves as President and Chief Executive Officer of Electromed, Inc. Prior to joining Electromed in July of 2023, he served as President and Chief Executive Officer of Provista, Inc. (2017 2022) and of Denver Solutions, LLC (2015 2017). James L. Cunniff has extensive executive leadership experience, having served as President and CEO and Board Member at Electromed, Inc., as well as President and CEO at Provista, Inc. He also held the positions of President, CEO, and Board Member at Denver Solutions LLC (d/b/a Leiters Health). Prior to these roles, he was Senior Vice President, Americas at Acelity L.P. Inc., and President of Multiple Divisions at Stryker Corporation. He holds a BA in Advertising and Business from the University of Illinois Urbana Champaign and completed the Advanced Management Program at Harvard Business School. - James L. Cunniff是医疗保健领域一位经验丰富的高管，直接了解Electromed的业务和运营，因为他目前担任Electromed, Inc.的总裁兼首席执行官。在2023年7月加入Electromed之前，他曾担任Provista，Inc.（20172022）和Denver Solutions，LLC（20152017）的总裁兼首席执行官。James L. Cunniff拥有丰富的行政领导经验，曾在Electromed, Inc.担任总裁兼首席执行官、董事会成员，并在Provista，Inc.担任总裁兼首席执行官。他还曾在Denver Solutions LLC（d/b/a Leiters Health）担任总裁、首席执行官和董事会成员等职务。在担任这些职务之前，他曾担任Acelity L.P. Inc.美洲区高级副总裁，以及史赛克公司多个部门总裁。他拥有伊利诺伊大学厄巴纳香槟分校的广告和商业学士学位，并在哈佛商学院完成了高级管理课程。
- James L. Cunniff is a seasoned executive in the healthcare space with a direct knowledge of Electromed's business and operations as he currently serves as President and Chief Executive Officer of Electromed, Inc. Prior to joining Electromed in July of 2023, he served as President and Chief Executive Officer of Provista, Inc. (2017 2022) and of Denver Solutions, LLC (2015 2017). James L. Cunniff has extensive executive leadership experience, having served as President and CEO and Board Member at Electromed, Inc., as well as President and CEO at Provista, Inc. He also held the positions of President, CEO, and Board Member at Denver Solutions LLC (d/b/a Leiters Health). Prior to these roles, he was Senior Vice President, Americas at Acelity L.P. Inc., and President of Multiple Divisions at Stryker Corporation. He holds a BA in Advertising and Business from the University of Illinois Urbana Champaign and completed the Advanced Management Program at Harvard Business School.
- Gregory J. Fluet
-
Gregory J. Fluet目前担任Ferring Microbiome Inc.（FKA Rebiotix）的首席运营官和现场主管，该公司是Ferring Pharmaceuticals旗下公司，专注于通过基于微生物组的产品彻底改变使人衰弱的疾病的治疗方法。自2016年起，他在Rebiotix工作，包括从2017年4月起担任首席商务官，直到该公司于2018年4月被Ferring Pharmaceuticals收购。此前，Fluet先生曾担任Urologix, Inc.的首席执行官，该公司当时是一家上市公司，也是基于办公室的微创良性前列腺增生（BPH）疗法的开发商。Gregory J. Fluet拥有丰富的执行领导经验，曾担任Ferring Microbiome Inc.（FKA Rebiotix）的首席运营官，以及Urologix, Inc.，Inc.的首席执行官、临时首席财务官以及执行副总裁兼首席运营官。在其职业生涯的早期，他是Sapient Capital Management LLC的合伙人。他拥有斯坦福大学机械工程学士学位。
Gregory J. Fluet currently serves as Chief Operating Officer and Site Head for Ferring Microbiome Inc. (fka Rebiotix), a Ferring Pharmaceuticals company focused on revolutionizing the treatment of debilitating diseases through microbiome based products. Since 2016 he worked at Rebiotix, including serving as Chief Business Officer from April 2017 until the company's acquisition by Ferring Pharmaceuticals in April 2018. Previously, Mr. Fluet served as Chief Executive Officer of Urologix, Inc., then a public company and developer of minimally invasive office based Benign Prostatic Hyperplasia (BPH) therapies. Gregory J. Fluet has extensive executive leadership experience, having served as COO of Ferring Microbiome Inc. (fka Rebiotix), as well as CEO, Interim CFO, and Executive VP and COO at Urologix, Inc. Earlier in his career, he was an Associate at Sapient Capital Management LLC. He holds a BS in Mechanical Engineering from Stanford University. - Gregory J. Fluet目前担任Ferring Microbiome Inc.（FKA Rebiotix）的首席运营官和现场主管，该公司是Ferring Pharmaceuticals旗下公司，专注于通过基于微生物组的产品彻底改变使人衰弱的疾病的治疗方法。自2016年起，他在Rebiotix工作，包括从2017年4月起担任首席商务官，直到该公司于2018年4月被Ferring Pharmaceuticals收购。此前，Fluet先生曾担任Urologix, Inc.的首席执行官，该公司当时是一家上市公司，也是基于办公室的微创良性前列腺增生（BPH）疗法的开发商。Gregory J. Fluet拥有丰富的执行领导经验，曾担任Ferring Microbiome Inc.（FKA Rebiotix）的首席运营官，以及Urologix, Inc.，Inc.的首席执行官、临时首席财务官以及执行副总裁兼首席运营官。在其职业生涯的早期，他是Sapient Capital Management LLC的合伙人。他拥有斯坦福大学机械工程学士学位。
- Gregory J. Fluet currently serves as Chief Operating Officer and Site Head for Ferring Microbiome Inc. (fka Rebiotix), a Ferring Pharmaceuticals company focused on revolutionizing the treatment of debilitating diseases through microbiome based products. Since 2016 he worked at Rebiotix, including serving as Chief Business Officer from April 2017 until the company's acquisition by Ferring Pharmaceuticals in April 2018. Previously, Mr. Fluet served as Chief Executive Officer of Urologix, Inc., then a public company and developer of minimally invasive office based Benign Prostatic Hyperplasia (BPH) therapies. Gregory J. Fluet has extensive executive leadership experience, having served as COO of Ferring Microbiome Inc. (fka Rebiotix), as well as CEO, Interim CFO, and Executive VP and COO at Urologix, Inc. Earlier in his career, he was an Associate at Sapient Capital Management LLC. He holds a BS in Mechanical Engineering from Stanford University.
- Kathleen A. Tune
-
Kathleen A. Tune目前是Thomas, McNerney & Partners的合伙人。2000年到2003年期间，Tune女士曾受雇于Piper Jaffray Companies，并在此担任一名保健分析师，与医疗科技公司合作。在Piper的时候，她曾和包括医疗设备，医药攻击和诊断领域公司合作过。她曾受雇于Solvay, S.A.，并在现在属于Pfizer的一个部门工作，负责新产品的开发；还曾担任University of Minnesota高级科学人员。Tune女士目前在私营的Asante Solutions, Inc., AxioMed Spine Corporation以及 VertiFlex, Inc.三个机构的董事会任职，并且还是非盈利性的Mid-America Health Care Investors Network （MHIN）的总裁。她的教育背景包括University of Minnesota微生物学硕士学位和University of Minnesota商学院的工商管理硕士学位。
Kathleen A. Tune currently serves as Managing Partner with Capita3, an early stage venture capital fund focused on next generation healthcare startup founders, since January 2019. Ms. Tune was the CFO/COO for Marani Health, Inc., a leading development stage maternal and fetal health company, from 2020 through February 2024 and is a former Partner at Thomas, McNerney & Partners, where she led and managed an investment portfolio with a primary focus in healthcare technologies from 2003 to December 2019. Kathleen A. Tune has extensive experience across venture capital, healthcare, and finance, having served as Managing Partner at Capita3, CFO/COO at Marani Health, Inc., and Partner at Thomas, McNerney & Partners. Earlier in her career, she was an Equity Analyst at Piper Sandler and a Program Manager at Pfizer. She holds a BS in Biochemistry and Microbiology from Minnesota State University, an MS in Veterinary Microbiology from the University of Minnesota, and an MBA in Finance from the University of Minnesota Carlson School of Management. - Kathleen A. Tune目前是Thomas, McNerney & Partners的合伙人。2000年到2003年期间，Tune女士曾受雇于Piper Jaffray Companies，并在此担任一名保健分析师，与医疗科技公司合作。在Piper的时候，她曾和包括医疗设备，医药攻击和诊断领域公司合作过。她曾受雇于Solvay, S.A.，并在现在属于Pfizer的一个部门工作，负责新产品的开发；还曾担任University of Minnesota高级科学人员。Tune女士目前在私营的Asante Solutions, Inc., AxioMed Spine Corporation以及 VertiFlex, Inc.三个机构的董事会任职，并且还是非盈利性的Mid-America Health Care Investors Network （MHIN）的总裁。她的教育背景包括University of Minnesota微生物学硕士学位和University of Minnesota商学院的工商管理硕士学位。
- Kathleen A. Tune currently serves as Managing Partner with Capita3, an early stage venture capital fund focused on next generation healthcare startup founders, since January 2019. Ms. Tune was the CFO/COO for Marani Health, Inc., a leading development stage maternal and fetal health company, from 2020 through February 2024 and is a former Partner at Thomas, McNerney & Partners, where she led and managed an investment portfolio with a primary focus in healthcare technologies from 2003 to December 2019. Kathleen A. Tune has extensive experience across venture capital, healthcare, and finance, having served as Managing Partner at Capita3, CFO/COO at Marani Health, Inc., and Partner at Thomas, McNerney & Partners. Earlier in her career, she was an Equity Analyst at Piper Sandler and a Program Manager at Pfizer. She holds a BS in Biochemistry and Microbiology from Minnesota State University, an MS in Veterinary Microbiology from the University of Minnesota, and an MBA in Finance from the University of Minnesota Carlson School of Management.
- Kathleen S. Skarvan
-
Kathleen S. Skarvan由非管理董事向Electromed, Inc.的董事会推荐担任提名与治理委员会成员。自2012年12月起一直担任公司的首席执行官。从2011年11月到2012年10月担任OEM Fabricators的运营副总裁。在此之前，在Hutchinson Technology Incorporated担任各种角色，最后从2007年4月至2011年3月担任磁盘驱动器组件事业部的总裁，管理一家年收入超过3亿美元的上市公司事业部。2010年12月至2011年3月担任Hutchinson Technology Incorporated的高级副总裁。自2003年10月到2007年4月，担任磁盘驱动器组件事业部和营销部副总裁。
Kathleen S. Skarvan served as Electromed, Inc.'s President and Chief Executive Officer from 2012 until her retirement on June 30, 2023. Prior to Electromed, Ms. Skarvan served as Vice President of Operations at OEM Fabricators, a leading custom metal fabrication company specializing in building components (Sep 2011 Oct 2012). In addition, Ms. Skarvan held several positions of increasing responsibility over her 29 year career at Hutchinson Technology, Inc. and was responsible for a division with annual revenues in excess of $300 million, managing 3,500 employees across R&D, marketing, sales, and technical support in five countries. Kathleen S. Skarvan has extensive executive leadership experience, having served as President and CEO of Electromed, Inc. Previously, she was VP of Operations at OEM Fabricators and served as SVP and President of the Disk Drive Components Division at Hutchinson Technology, Inc. She holds a BA in Mass Communications from St. Cloud State University. - Kathleen S. Skarvan由非管理董事向Electromed, Inc.的董事会推荐担任提名与治理委员会成员。自2012年12月起一直担任公司的首席执行官。从2011年11月到2012年10月担任OEM Fabricators的运营副总裁。在此之前，在Hutchinson Technology Incorporated担任各种角色，最后从2007年4月至2011年3月担任磁盘驱动器组件事业部的总裁，管理一家年收入超过3亿美元的上市公司事业部。2010年12月至2011年3月担任Hutchinson Technology Incorporated的高级副总裁。自2003年10月到2007年4月，担任磁盘驱动器组件事业部和营销部副总裁。
- Kathleen S. Skarvan served as Electromed, Inc.'s President and Chief Executive Officer from 2012 until her retirement on June 30, 2023. Prior to Electromed, Ms. Skarvan served as Vice President of Operations at OEM Fabricators, a leading custom metal fabrication company specializing in building components (Sep 2011 Oct 2012). In addition, Ms. Skarvan held several positions of increasing responsibility over her 29 year career at Hutchinson Technology, Inc. and was responsible for a division with annual revenues in excess of $300 million, managing 3,500 employees across R&D, marketing, sales, and technical support in five countries. Kathleen S. Skarvan has extensive executive leadership experience, having served as President and CEO of Electromed, Inc. Previously, she was VP of Operations at OEM Fabricators and served as SVP and President of the Disk Drive Components Division at Hutchinson Technology, Inc. She holds a BA in Mass Communications from St. Cloud State University.
高管简历
中英对照 | 中文 | 英文- James L. Cunniff
James L. Cunniff是医疗保健领域一位经验丰富的高管，直接了解Electromed的业务和运营，因为他目前担任Electromed, Inc.的总裁兼首席执行官。在2023年7月加入Electromed之前，他曾担任Provista，Inc.（20172022）和Denver Solutions，LLC（20152017）的总裁兼首席执行官。James L. Cunniff拥有丰富的行政领导经验，曾在Electromed, Inc.担任总裁兼首席执行官、董事会成员，并在Provista，Inc.担任总裁兼首席执行官。他还曾在Denver Solutions LLC（d/b/a Leiters Health）担任总裁、首席执行官和董事会成员等职务。在担任这些职务之前，他曾担任Acelity L.P. Inc.美洲区高级副总裁，以及史赛克公司多个部门总裁。他拥有伊利诺伊大学厄巴纳香槟分校的广告和商业学士学位，并在哈佛商学院完成了高级管理课程。
James L. Cunniff is a seasoned executive in the healthcare space with a direct knowledge of Electromed's business and operations as he currently serves as President and Chief Executive Officer of Electromed, Inc. Prior to joining Electromed in July of 2023, he served as President and Chief Executive Officer of Provista, Inc. (2017 2022) and of Denver Solutions, LLC (2015 2017). James L. Cunniff has extensive executive leadership experience, having served as President and CEO and Board Member at Electromed, Inc., as well as President and CEO at Provista, Inc. He also held the positions of President, CEO, and Board Member at Denver Solutions LLC (d/b/a Leiters Health). Prior to these roles, he was Senior Vice President, Americas at Acelity L.P. Inc., and President of Multiple Divisions at Stryker Corporation. He holds a BA in Advertising and Business from the University of Illinois Urbana Champaign and completed the Advanced Management Program at Harvard Business School.- James L. Cunniff是医疗保健领域一位经验丰富的高管，直接了解Electromed的业务和运营，因为他目前担任Electromed, Inc.的总裁兼首席执行官。在2023年7月加入Electromed之前，他曾担任Provista，Inc.（20172022）和Denver Solutions，LLC（20152017）的总裁兼首席执行官。James L. Cunniff拥有丰富的行政领导经验，曾在Electromed, Inc.担任总裁兼首席执行官、董事会成员，并在Provista，Inc.担任总裁兼首席执行官。他还曾在Denver Solutions LLC（d/b/a Leiters Health）担任总裁、首席执行官和董事会成员等职务。在担任这些职务之前，他曾担任Acelity L.P. Inc.美洲区高级副总裁，以及史赛克公司多个部门总裁。他拥有伊利诺伊大学厄巴纳香槟分校的广告和商业学士学位，并在哈佛商学院完成了高级管理课程。
- James L. Cunniff is a seasoned executive in the healthcare space with a direct knowledge of Electromed's business and operations as he currently serves as President and Chief Executive Officer of Electromed, Inc. Prior to joining Electromed in July of 2023, he served as President and Chief Executive Officer of Provista, Inc. (2017 2022) and of Denver Solutions, LLC (2015 2017). James L. Cunniff has extensive executive leadership experience, having served as President and CEO and Board Member at Electromed, Inc., as well as President and CEO at Provista, Inc. He also held the positions of President, CEO, and Board Member at Denver Solutions LLC (d/b/a Leiters Health). Prior to these roles, he was Senior Vice President, Americas at Acelity L.P. Inc., and President of Multiple Divisions at Stryker Corporation. He holds a BA in Advertising and Business from the University of Illinois Urbana Champaign and completed the Advanced Management Program at Harvard Business School.
- Bradley M. Nagel
Bradley M. Nagel于2022年11月加入Electromed，担任公司首席财务官、财务主管和秘书。在加入Electromed之前，Nagel先生最近于2018年6月至2022年11月在美敦力 plc担任全球肺部健康和可视化部门首席财务官。此前，曾任职于美敦力,2016年至2018年6月担任高级经理，会计和销售运营部，2015年至2016年担任会计部经理。在加入美敦力之前，Nagel先生曾在塔吉特公司和TCF金融公司担任销售、运营和会计方面的各种职责。Nagel先生拥有加尔文大学商业与金融学士学位。
Bradley M. Nagel joined Electromed in November 2022 as the Company's Chief Financial Officer, Treasurer and Secretary. Prior to joining Electromed, Mr. Nagel most recently served as Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic plc from June 2018 to November 2022. Previously, he served at Medtronic as Sr. Manager, Accounting and Sales Operations from 2016 to June 2018 and Accounting Manager from 2015 to 2016. Before joining Medtronic, Mr. Nagel held various roles of increasing responsibility in sales, operations and accounting at Target Corporation and TCF Financial Corporation. Mr. Nagel holds a bachelor's degree in business & finance from Calvin University.- Bradley M. Nagel于2022年11月加入Electromed，担任公司首席财务官、财务主管和秘书。在加入Electromed之前，Nagel先生最近于2018年6月至2022年11月在美敦力 plc担任全球肺部健康和可视化部门首席财务官。此前，曾任职于美敦力,2016年至2018年6月担任高级经理，会计和销售运营部，2015年至2016年担任会计部经理。在加入美敦力之前，Nagel先生曾在塔吉特公司和TCF金融公司担任销售、运营和会计方面的各种职责。Nagel先生拥有加尔文大学商业与金融学士学位。
- Bradley M. Nagel joined Electromed in November 2022 as the Company's Chief Financial Officer, Treasurer and Secretary. Prior to joining Electromed, Mr. Nagel most recently served as Divisional Chief Financial Officer of Global Lung Health and Visualization at Medtronic plc from June 2018 to November 2022. Previously, he served at Medtronic as Sr. Manager, Accounting and Sales Operations from 2016 to June 2018 and Accounting Manager from 2015 to 2016. Before joining Medtronic, Mr. Nagel held various roles of increasing responsibility in sales, operations and accounting at Target Corporation and TCF Financial Corporation. Mr. Nagel holds a bachelor's degree in business & finance from Calvin University.